VACCINE THERAPY FOR MULTIPLE MYELOMA ALLOGENEIC DENDRITIC CELLS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This phase I/II study will evaluate primarily the feasibility and safety in thirty (30) patients with multiple myeloma who will be vaccinated with allogeneic dendritic cell autologous idiotype-KLH vaccine. Stage 1 of the study will enroll 15 patients who meet eligibility criteria. If a sufficient number of patients complete vaccination in the first cohort and there is no increase incidence of Acute Graft versus Host Disease (GVHD), then an additional 15 patients will be enrolled to complete stage 2 of the study. A minimum of 1X106 allogeneic dendritic cells pulsed with autologous idiotype-KLH protein will be given in 1cc and delivered intradermally in each of five subsequent vaccinations given on a once monthly schedule.